Novo Nordisk Receivables 2010-2024 | NVO

Novo Nordisk receivables for the quarter ending September 30, 2024 were $11.737B, a 29.74% increase year-over-year.

  • Novo Nordisk receivables for 2023 were $10.928B, a 34.2% increase from 2022.
  • Novo Nordisk receivables for 2022 were $8.143B, a 9.36% increase from 2021.
  • Novo Nordisk receivables for 2021 were $7.446B, a 51.01% increase from 2020.

Novo Nordisk Receivables 2010-2024 | NVO

  • Novo Nordisk receivables for 2023 were $10.928B, a 34.2% increase from 2022.
  • Novo Nordisk receivables for 2022 were $8.143B, a 9.36% increase from 2021.
  • Novo Nordisk receivables for 2021 were $7.446B, a 51.01% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B